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The progression of cells through  the mitotic cycle is characterized not  only 
by ordered  changes  in  cellular functions  concerned  with  DNA  synthesis  and 
mitosis,  but  also  by  numerous  physical  and  chemical  alterations  in  other 
properties of the  cell.  Many cell cycle-dependent changes in  the  external  cell 
membrane have been described including gross alterations in physical structure 
(1,  2)  and fluctuations  in  synthesis of enzymes and  cell products such  as  im- 
munoglobulins  (3,  4).  Changes  in  the  structure  of  the  cell  membrane  are  of 
particular interest  because alterations in  the properties of the  cell  surface are 
believed  to  contribute  to  the  disordered  proliferations  which  characterize 
malignant cells. 
Previous work has shown that the human cultured cell line WI-L2 does not 
vary during its growth cycle in susceptibility to lysis in the cytotoxic test with 
complement and  antibodies  directed  against  the  antigens  of the  major histo- 
compatibility locus in man  (HL-A)  (5). On  the other hand,  the susceptibility 
of certain  cell  lines  to  lysis induced  by antibody directed  against  membrane 
antigens and complement, changes during the growth cycle. This phenomenon 
has been demonstrated  for several cell lines including  the murine  tumor lines 
YCAB  (6,  7),  YAC  (8),  L  1210  (9),  and  Chinese  hamster lung cells  (10).  In 
each  of  these  cell  lines  the  times  of  maximal  and  minimal  susceptibility  to 
complement-mediated  lyric  damage  corresponded  to  the  G1  and  S  phases, 
respectively. In the  case of murine  tumor cells,  the  expression of cell surface 
histocompatibility  antigens,  as  evidenced  by the  ability  of cells  to  quantita- 
tively absorb alloantisera directed against histocompatibility antigen was most 
pronounced during  the period of maximal lytic susceptibility. However, addi- 
tional studies of the murine tumor cell line YCAB did not support the conten- 
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tion that these variations in antigenic expression led to an increased ability to 
activate  the  complement system  in  free  solution or  on  the  cell  surface  since 
complement  activation  and  late  complement  component  binding to  the  cell 
surface  remained  constant  throughout  the  cell  cycle  (7,  11).  In  the  present 
study we  have examined a  human cell line (RPMI  8866)  which  also  exhibits 
variability in cytolytic susceptibility during the cell cycle but which does not 
show  significant variation in  the  cell  surface  expression of  histocompatibility 
antigens.  These  data  suggest  that  variables  other  than  antigenic expression, 
antibody binding, and complement activation are responsible for the variation 
in susceptibility of complement-mediated damage during certain phases of the 
cell cycle. 
Materials and Methods 
Cultured Human Lymphoid Cell Line.--Cultured human lymphoid ceils RPMI 8866 (HL-A 
2, 3, 7, 12) derived from a donor with myelogenous leukemia (12) were grown in suspension 
in medium RPMI  1640 with  10% fetal calf serum, Cell concentration and viability were 
determined by try-pan blue exclusion and use of a hemacytometer. 
HL-A  Alloantisera.--Antisera  were  obtained from the National Institute of Allergy and 
Infectious Diseases serum bank and from the laboratories of Doctors R. Ceppellini, R. Payne, 
and P. I. Terasaki. All sera had been frozen and thawed several times. 
Rabbit Antihuman  Lymphocyte Serum.--This antiserum was produced as previously de- 
scribed (13) and had a titer of 1:16,000  against cultured human lymphoid cells in the micro- 
lymphocytotoxic test. 
Rabbit Natural  Antihuman  Lymphocyte Antibodies.--Rabbit IgM antihuman lymphocyte 
antibodies were  isolated from fresh normal rabbit serum by sequential ammonium sulfate 
fracfionation and gel filtration on Sephadex  G-200 (14). 
Complement.--Rabbit  complement was a pool of nine rabbit sera selected  after individual 
blood samples proved nontoxic to peripheral lymphocytes from four randomly chosen subjects 
in the cytotoxic assay. This complement was absorbed with cultured human lymphoid cells 
in the presence of EDTA (final concentration 10 mM) at 4°C for  60 min (15).  Guinea pig 
complement was a pool of eight guinea pig sera. A pool of fresh sera derived from five healthy 
donors with no previous history of pregnancy or blood transfusion served as the human com- 
plement source. Complement pools were stored at -- 70°C in small samples and were used only 
once after thawing. Human complement components C4, C3, and C8, purified from human 
serum (16, 17), were radiolabeled with ~25I by the chloramine-T method (18) without loss of 
activity. The specific radioactivity of C4, C3, and C8 was, respectively, 2.2 X  105, 2.2 X  105, 
and 4.5 X  106 cpm/gg; these values correspond to 0.22, 0.22, and 0.45/zCi/gg. 
Cell Synchronization.--RPMI 8866 cells were  synchronized as previously described  (19). 
Briefly, cultures were seeded at 2 X  105 cells/ml; when the DNA synthesis rate, as judged by 
incorporation of tritiated thymidine, was approximately 2-10% of the maximum (Go phase 
of cell growth),  resting cells were  harvested and resuspended in fresh,  37°C  medium. Cell 
number and course of DNA synthesis were then ascertained in order to identify the G1 and 
S phases. 
Cytotoxic Assay.--This assay was performed as a dye exclusion test (15). When cultured 
human lymphoid cells were the target cells, absorbed rabbit complement, guinea pig comple- 
ment, or human complement  were used. When peripheral human lymphocytes were the targets, 
undiluted fresh rabbit serum was the complement source. 
Quantitation of Cell-Bound Radiolabded C4, C3, and CS.--At various stages of the growth 
cycle,  5  X  105 RPMI 8866 cells  (washed  three  times with Hank's balanced salt solution 580  HL-A  ANTIGENS~  COMPLEMENT~  AND  IMMUNE  LYSIS 
[HBSS] 1) were mixed with 20 #1 of antisera (previously inactivated at 56°C for 30 rain) and 
40 #1 of complement, the latter containing radiolabeled C4, C3, or C8. After 60 rain of incuba- 
tion at 37°C, cells were washed four times and analyzed for radioactivity in a well type scin- 
tillation counter. Reaction mixtures with heat-inactivated normal human serum in place of 
specific  antisera were used to screen for nonspecific binding of complement components. Mol 
wt of 200,000,  185,000,  and 150,000 were used to calculate the number of bound C4, C3, and 
C8 molecules, respectively. 
Mieroabsorption Technique.--Quantitative microabsorption tests were performed as previ- 
ously described (20). The results were expressed in terms of absorption dosage 5o (AD 5o), i.e., 
the number of cells required to reduce by 50% the cytotoxicity of an alloantiserum used at a 
concentration twice that required to lyse 95% of selected target cells. 
Isotopic Antiglobulin  Test.--A rabbit antihuman IgG serum was fractionated by ion ex- 
change chromatography on DEAE cellulose in 0.01 M phosphate buffer, pH 8. The IgG frac- 
tion was checked for specificity by immunoelectrophoresis against human IgG and labeled 
with 125I (New England Nuclear, Boston, Mass.) by the chloramine-T method (18) at a spec 
act of 0.9 mCi//~g of protein. 
For the test, 2  X  105 RPMI 8866 cells in Go,  G1, and S phases of the growth cycle were 
washed twice with HBSS and incubated with 20 #1 of HL-A alloantisera for 60 rain at room 
temperature in Beckman microtubes  (Beckman Instruments, Inc.,  Spinco Div.,  Palo Alto, 
Calif.).  The cells were  washed  three times with HBSS,  10/zl of radiolabeled diluted anti- 
globulin reagent were added  then, and the reaction mixtures again incubated for 60 min at 
room temperature. Next, the cells were washed three times and analyzed for radioactivity in a 
well type scintillation counter. Nonspecific binding of labeled antiglobulin reagent was deter- 
mined from control reaction mixtures in which normal human serum was used. Specific binding, 
expressed in cpm, was calculated by subtracting the values for nonspecific uptake from the 
values for total bound radioactivity. 
Extraction  and  Serologic  Evaluation  of Soluble tlL-A  Alloantigens.--Soluble  HL-A  allo- 
antigens were extracted from cultured cells by the 3M KC1 method (21). The specific antigenic 
activity of soluble HL-A antigens was evaluated as ability to specifically inhibit cytotoxicit~ 
of  operationally monospecific HL-A  alloantisera against selected  target cells in  the  micro- 
cytotoxic  test.  Immunologic potency of soluble HL-A preparations was expressed as IDs0 
inhibition dosage  (22),  i.e.,  the  minimum amount  of  soluble  HL-A  antigens necessary  to 
specifically inhibit 50% of the activity of monospecific cytotoxic alloantisera. Immunologic 
specificity of the preparations was expressed in terms of specificity ratio (SR)  (22,  23), i.e., 
the ratio between the degree to which antigens inhibit antisera directed against determinants 
absent from the cell source, as compared to those directed against determinants present on the 
cell source. 
Determination of Cell  Volume.--This determination was done as previously described (19). 
Protein Concentration.--Protein was determined by a  modification of the Lowry method 
(24); lysozyme was used as a standard. 
Rosette  Formation Test.--This was performed as previously described  (25).  Briefly, sheep 
erythrocytes coated with rabbit antisheep hemolysin (BBL, Bioquest Div., Cockeysville, Md.) 
(EA)  and  purified  human  C1, 4,  2  (EAC142hu), C1,  4,  2,  3  (EAC1-3hu),  or  CS-deficient 
mouse  serum  from  strain B10.D2  old  (EAC1-3m°),  were  adjusted  to 5  )<  107  cells/ml in 
phosphate-buffered saline (PBS), pH  7.2.  200 /zl  of  RPMI  8866  cell  suspension (1  X  106 
cells/ml HBSS)  were  incubated  with  200 #1  of  EAC1-3 hu  or  EAC1-3 m°  and  200/zl  PBS 
with 0.06 M  EDTA in a vertical submersion rotator at 37°C  for 10 min. At the end of the 
incubation, 250-300 lymphoid cells were counted; those having three or more EAC1-3  cells 
attached were considered rosette positive. EAC142 hu and EA cells were included as controls. 
1 Abbreviations used in  this paper:  ADs0,  absorption dosages0;  HBSS,  Hank's  balanced 
salt solution; PBS, phosphate-buffered solution; SR, specificity ratio. PELLEGRINO~  FERRONE,  COOPER~ DIERICH~  AND  REIS~ELD  581 
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RESULTS 
Relationship  between  the  Phase of the  Growth Cycle  and the  Susceptibility  of 
RPMI 8866 Cells to Immune Lysis in the Lymphocytotoxic  Test.--To determine 
the relationship between the phase of the growth cycle and susceptibility to 
lysis mediated by HL-A alloantisera directed against antigens of the first and 
second segregant series,  cells in synchronous growth were sampled in various 
phases of the growth cycle and incubated with HL-A alloantisera and rabbit 
complement. Fig. 1 shows that cells in the Ga phase were approximately two- 
fold less sensitive than those in the Go or S phases of the growth cycle to the 
cytolytic potential of alloantisera directed against HL-A2. Similar results were 
obtained with alloantisera directed against HL-A7, a specificity of the second 
segregant series.  Rabbit serum is known to contain natural antibodies directed 
against a  polymorphic system of antigens present on human lymphoid cells 
(26,  27).  To eliminate the possibility that the variation in the lysis obtained 
with HL-A alloantisera and rabbit  complement was due only to  changes in 
the  expression  of  the  antigenic  determinants  towards  which  these  natural 
rabbit antibodies are directed, the cytotoxic test was repeated utilizing human 
and guinea pig sera, which do not contain antibodies directed against cultured 
human lymphoid cells, as the sources of complement. Although both of these 
complement sources were cytolytically less efficient than rabbit  complement, 
the lyric pattern observed was identical to that found with rabbit complement 
and HL-A alloantisera (Fig. 1). In order to determine whether variable suscepti- 
bility to lysis applied also to other antigen systems, RPMI 8866 cells at various 
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FIG.  I.  Relationship  between  the growth cycle and  susceptibility  to  lysis of lymphoid 
cells RPMI 8866 by HL-A alloantisera and complement. On the left, the growth curve and 
DNA synthesis of the cells is depicted. The small panels illustrate the susceptibility of RPMI 
8866 ceils to the lyric activity of anti-HL-A2 (upper panels) and anti-HL-A7 (lower panels) 
in conjunction with rabbit  (A, D), human  (B,  E), and guinea pig (C, F) complement. The 
growth phase of the target cells is indicated by the corresponding symbol in the growth curve. 
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phases of the  growth  cycle were  reacted  with  rabbit  IgM  which  contains  the 
natural  antibodies  directed  against  human  lymphocytes  and  human  comple- 
ment. Cells in the G1 phase were again found to be least sensitive to cytotoxicity 
(Fig.  2). 
These  results  indicate  that  RPMI  8866  cells  change  in  susceptibility  to 
immune  lysis throughout  their growth  cycle, with  cells in  the  G1 phase being 
more resistant  than cells in other portions of the cell cycle to the lyric activity 
of  HL-A  alloantisera  and/or  rabbit  natural  antibodies  in  conjunction  with 
complement components supplied by either rabbit, human, or guinea pig serum. 
Antibody-Binding Capacity of RPMI 8866 Cells during the Growth Cycle.--To 
analyze  the  possibility  that  variability  in  susceptibility  to  lysis  was  due  to 
changes in the density of HL-A antigens during  the  cell cycle,  we determined 
whether cells sampled from various phases of the growth cycle differed in their 
ability  to bind  HL-A  alloantibodies.  Two  tests were  utilized  in  these  studies. 
First,  cells  sampled  from  various  phases  of  the  growth  cycle  were  used  in 
quantitative  absorption  tests with HL-A alloantisera.  As indicated  in Table I, 
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FIG. 2.  Cytolytic activity of rabbit IgM and  human complement towards  RPMI 8866 
cells in different stages of their growth cycle as indicated  by the corresponding symbol in the 
growth curve depicted in Fig. 1. 
TABLE I 
A bsorbing Capacity of Synchronized Populations of Cultured Human Lymphoid Calls  RPMI 8866 
Phase of cell  ADso* 
cycle  HL-A2  HL-A3  HL-A5  HL-A7  HL-A8 
Go  900  1,200  --.~  600  -- 
G1  900  1,100  --  700  -- 
S  300  500  --  250  -- 
* Number of cells required  to reduce by 50% the cytotoxicity of an alloantiserum. 
:[: Indicates ADs0 values  > 50,000. PELLEGRINO, FERRONE~ COOPER, DIERICH, AND REISFELD  583 
cells  sampled from the  Go and  G~ phases were equally able to absorb  HL-A 
alloantisera directed against specificities of the first and second segregant series. 
Cells in the S phase had an approximately twofold higher absorbing capacity 
than those in the Go and G~ phases. However, as RPMI 8866 cells have a two- 
to threefold larger volume during S than during Go or GI, it is likely that the 
HL-A antigenic density is  relatively constant throughout the  cell  cycle. To 
determine whether qualitative differences of HL-A antigens could be detected 
during the growth cycle, the curves relating percent absorption to number of 
cells needed for absorption in different stages of the growth cycle were com- 
pared. The absorption curves of cells in the Go or G~ phases were superimposa- 
ble. The absorption curve obtained with cells  in the S phase was also super- 
imposable on those obtained for Go and G~ cells when the values for this curve 
were multiplied by a  constant factor (2.9  for HL-A2, 2.1  for HL-A3, and 2.6 
for HL-A7).  As  discussed  by  Ohanian  et  al.  (28),  these  findings constitute 
presumptive  evidence that  the  antigens being  compared  are  very similar or 
identical. 
In the second test, an isotopic antiglobulin assay was used to quantitate the 
antigenic density of cells sampled in various phases of the cell cycle. In this 
test cells were incubated with HL-A alloantisera, washed, and then incubated 
with  radiolabeled  rabbit  antihuman  IgG  antibodies.  Specific  binding  of the 
second radioactively labeled antibody is a  function of the number of bound 
HL-A antibodies and  thus,  indirectly, of the number of accessible  antigenic 
sites. As was observed in the quantitative absorption assay, Go and  G~ cells 
exhibited  similar binding  capacities  while cells  sampled during  the  S  phase 
absorbed two to three times more antibody (Fig. 3).  For reasons already dis- 
cussed,  this  difference probably  reflects  changes  in  cell  volume  during  the 
growth cycle. 
To further assess  the number and distribution of HL-A antigens during the 
cell cycle, HL-A antigens were extracted in 3 M  KC1 from RPMI 8866 cells 
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Fro.  3.  Binding of  [125I]radiolabeled rabbit antihuman 5,-globulins by RPMI  8866 cells 
sampled from  Go (hatched-),  G1  (open-), and S  (closed-)  phases and sensitized with HL-A 
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TABLE II 
Sdubilization of HL-A Antigens  from Cultured Lymphoid Cells RPMI 8866 in Different Stages 
of Cell Growth 
Phase of cell cycle 
IDs0* units/10  9 cells (X10 -3) 
HL-A2  HL-A3  HL-A7 
Go  207  207  267 
G1  250  250  295 
S  245  245  295 
* Amount of antigen (expressed as/~g/#l) required for a 50% reduction of the cytotoxicity 
activity of an alloantiserum. This IDs0 value arbitrarily represents one unit of activity. 
-:  ::I  c,  c3  c, 
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Antisera 
FIG. 4.  Binding of [125IJradiolabeled complement components by RPMI 8866 cells sensi- 
tized with either HL-A  alloantisera, rabbit antihuman lymphocyte  serum or rabbit IgM and 
incubated with serum containing C4,  C3, or C8.  Cells were sampled from cultures in  Go 
(hatched-), G1 (open-), and S (closed-) phases. 
at various stages of their growth cycle. No difference was detected in the total 
amount of HL-A antigenic activity solubilized  throughout  the  growth  cycle, 
as  shown in Table  II, although twice as  much  protein  was solubilized  from 
cells in the Go phase than from cells in the G1 or S phases. This finding suggests 
that  larger  amounts  of  contaminating  proteins  are  solubilized  from  cells  in 
the Go phase. 
Binding  of Complement by Sensitized RPMI  8866  Cells.--In  order to deter- 
mine if the ability of RPMI 8866 cells  to bind complement varied during the 
growth cycle, cells  sampled in various phases of the cycle were sensitized with 
HL-A alloantisera, rabbit IgM natural antibody or rabbit ALS and mixed with 
rabbit,  human, or guinea pig complement containing radiolabeled human C3, 
C4,  or C8.  After incubation the cells  were washed and  the specifically bound 
radioactivity was determined. As shown in Fig. 4, cells sampled in the S phase 
generally exhibited a  two- to threefold greater ability to bind C4, C3, and C8 
after complement activation, than cells in the Go and G1 phases of the growth PELLEGRINO, FERRONE, COOPER, DIERICH, AND  REI$1~ELD  585 
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FIG. 5.  Binding of [125I]radiolabeled  complement components by RPMI  8866 ce]ls sensi- 
tized with HL-A2 alloantisera and incubated with either human, guinea pig, or rabbit comple- 
ment containing C4, C3, or C8. 
cycle. As discussed earlier, this probably reflects the larger volume of cells in 
the S phase. No significant difference was found between the four antisera in 
the amounts of radiolabeled C4 and C3 bound to the cells (Fig. 4), after incuba- 
tion with human complement containing labeled components. The amount of 
radiolabeled  C8  bound  was,  however,  greater  with  antihuman  lymphocyte 
serum, a finding which correlates with the considerably greater cytolytic poten- 
tial of this antiserum. Although only values for labeled components incorporated 
in human complement are shown, qualitatively identical results were obtained 
in comparable experiments with guinea pig and rabbit complement previously 
absorbed with human lymphoid cells. 
On comparing binding of the various components present in human, guinea 
pig, or rabbit complement, no significant difference in binding of C3  and  C4 
was observed when these components were incorporated in the three comple- 
ment  sources.  The  binding  of  C8,  however,  was  considerably greater  when 
incorporated  in  rabbit  sera  (Fig.  5).  This  finding correlates  with  the  more 
efficient cytolytic potential of rabbit complement. Although only values for S 
phase and for one antiserum (Stockenberg, anti-HL-A2) are shown in Fig. 5, 
comparable results were obtained with Go and G1 cells and with the other three 
antisera. 
Influence of the Cell Cycle on the Pathway of C Activation.--We  have recently 
shown that some HL-A alloantisera activate the classical pathway, others the 
alternate pathway, and a  third group both pathways of human complement 
(29).  In order  to  determine whether the pathway of complement activation 
changes during the cell  cycle, the lymphocytotoxic test was performed with 
RPMI 8866 cells sampled at various phases of the cell cycle with an alloanti- 
serum (Bizot, anti-HL-A2) which mediates lysis through the alternate pathway. 
Human serum in which the alternate pathway had been selectively inactivated 
by destruction of C3PA was employed as the complement source. If a change 
in the pathway of activation of complement occurred, one would expect the 
cytotoxic activity to become evident since the complement source contained 586  HL-A  ANTIGENS,  COMPLEMENT,  AND  IMMUNE  LYSIS 
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FIG. 6.  Activation of the alternate pathway of the human complement system by cells 
RPMI 8866 in Go (panel A), G1 (panel B), and S (panel C) phases sensitized with anti-HL-A2 
alloantisera. Control ( *--@ ) ; human complement added with EGTA at the final concentra- 
tion of 10 mM (LX--A); human complement deprived of C3PA by heating at 50°C for 20 
rain (C]--E]); human complement heated at 50°C for 20 min and added together with C3PA 
(o--o). 
adequate concentration of the components of the classical system. However, no 
lysis of cells sampled in Go, G1, and S phases was observed with the depleted 
complement  (Fig.  6).  The  target  cells  were  lysed  when  purified  C3PA  was 
restored to the depleted complement source and the relative amounts of lysis 
were as described earlier,  i.e.,  less lysis of cells occurred in  G1 phase.  On  the 
other  hand,  the  inactivation  of the  classical pathway of human  complement 
by selective chelation  of calcium did not  affect the pattern of ]ysis with  this 
alloantiserum. 
HL-A alloantisera have been shown to activate the classical pathway of the 
rabbit complement system (14).  In studies which are not shown, inhibition of 
this pathway by selective depletion of calcium in the reaction mixture prevented 
lysis of cells sampled in Go, G1, or S and sensitized with HL-A alloantibodies. 
Expression  of Other Cell Surface Markers during the Growth Cycle.--To deter- 
mine whether the expression of cell surface markers other than HL-A antigens 
changed during the growth cycle of RPMI 8866 cells, the reactivity of receptors 
for C3b and for degradation products of C3, presumably C3d,  was examined. 
Reactivity of RPMI 8866  cells with sensitized sheep erythrocytes coated with 
isolated  human  C1,  C4,  C2,  and  C3  did not  change  during  the  cell  cycle as 
evidenced by percentage of rosettes formed.  Reactivity with  sensitized sheep 
erythrocytes coated with  C5-deficient mouse serum also did  not vary during 
the  cell  cycle. Thus,  no variation  in  expression of receptors  for C3b  or  C3d 
degradation products was detected during the cell cycle. PELLEGRINO, FERR.ONE, COOPER, DIERICH, AND  REISFELD  587 
DISCUSSION 
Our results indicate that the susceptibility of a human lymphoblastoid cell 
line,  RPMI  8866,  to  complement-dependent lysis initiated  by  alloantibody 
directed against HL-A antigens or by heterologous antibody against membrane 
antigens varies with the phase of the cell cycle. The variation in susceptibility 
was approximately twofold with cells sampled in the G1 phase being less sensi- 
tive than cells examined in the Go or S phases of the cell cycle. In an attempt 
to explain this variability in lyric susceptibility we utilized three independent 
tests to assess density of HL-A antigens on the surface of RPMI 8866 cells in 
synchronous growth.  First, cells  sampled from various phases of the  growth 
cycle  were  used  in  quantitative  absorption  tests  with  HL-A  alloantisera. 
Second,  cells  were  reacted with HL-A  alloantisera followed by  radiolabeled 
antihuman IgG in an isotopic antiglobulin test, and third, HL-A antigens were 
extracted from RPMI 8866 cells at various stages of the growth cycle. These 
three independent tests fail to  reveal  any significant differences in  antigenic 
density between the  Go, G1, or S phases of the cycle when the  (1.5-2  times) 
greater volume of S cells was taken into account. The ability of cells to interact 
with the complement system was also found not to vary during the course of 
the cell  cycle. Thus,  cells  sampled in  Go,  G~, and S were equivalent in their 
ability after sensitization with various antisera  to  activate  the  complement 
system and to bind radiolabeled C3,  C4, and C8 incorporated in the comple- 
ment source. Further, studies revealed that the pathway of complement activa- 
tion,  whether alternate or  classical  depending on  the  source  of complement 
employed, did not change during the cell cycle. 
Although RPMI  8866  cells  exhibit variable  susceptibility to  complement- 
mediated lysis during the cell cycle as was observed with murine tumor cells 
YCAB (6, 7) and L  1210 (9), these cells differ from the murine tumor cell lines 
both in the phase of the growth cycle during which they are least susceptible 
to lysis and in the lack of change in antigen density during the growth cycle. 
Thus, YCAB and L  1210 cells were found to be most sensitive to complement- 
mediated cytolytic damage initiated by H-2 antibodies in the G~ phase of the 
cell cycle when the quantitative expression of antigen as determined by absorp- 
tion tests and extractibility was most pronounced. Taken together with the 
results  of  other  investigators,  these  studies  suggest  that  there  is  no  direct 
correlation between susceptibility to  lysis and  the  expression  of membrane- 
associated antigens. The body of evidence thus far accumulated also  suggests 
that variability in lyric susceptibility is not directly related to the ability of 
target cells to activate complement, to bind activated complement components 
or  to  sustain  complement-dependent  ultrastructural  lesions  (7,  11).  In  all 
probability, therefore, the differential susceptibility to lysis is due to changes in 
the properties of the cell membrane during the cell cycle. This is not unlikely 
in that many parameters of membrane function and structure are known to 
vary during cell  growth,  including turnover of membrane components  (30), 588  HL-A  ANTIGENS,  COMPLEMENT,  AND  IMMUNE  LYSIS 
fragility (1) and electrical potential (2, 31) of the cell membrane, formation of 
membrane associated  enzymes (32,  33),  synthesis of immunoglobulins  (3,  4), 
and susceptibility to infection by virus (34) and to oncogenic transformation by 
chemical (35). Alternatively, it may be that the cell membrane possesses the 
capacity to repair complement-induced damage at certain intervals during the 
cell cycle. 
The clinical relevance of these in vitro findings becomes apparent in planning 
immunotherapy regimen to combat neoplastic disease, e.g., when there is tumor 
cell growth while circulating antibodies are detected in a patient's serum. The 
G1 phase of the cell cycle varies with the cell line; tumor cells with a long G~ 
phase have a  far better chance of escaping antibody and complement action 
if their susceptibility to lysis varies as with RPMI 8866 cells.  If this is indeed 
the case in the in vivo situation, the efficacy of immunotherapy regimens could 
be greatly increased by planning therapy accordingly. 
SUMMARY 
Cultured  human  lymphoid  cells  RPMI  8866  at  different  stages  of  their 
growth cycle vary in their susceptibility to lysis by rabbit, human, and guinea 
pig  complement  activated  by  HL-A  antibodies  or  heterologous  antibodies 
directed  to  membrane  antigens;  cells in  G1 phase  are  the  least  sensitive  to 
lysis. To investigate the cause of differential susceptibility of cells RPMI 8866 
to lysis, the expression of HL-A determinants and the ability of cells to  react 
with  complement were investigated.  No  change  was  detected in  the  density 
of HL-A antigens on RPMI 8866  cells in synchronous growth as  determined 
by quantitative microabsorption assays,  isotopic antiglobulin tests and yields 
of soluble HL-A antigens. Cells did not vary during the growth cycle in  their 
ability to interact with complement components and in their capacity to  ac- 
tivate the complement system through the classical or alternate pathway. These 
data  suggest  that  variability in  lyric susceptibility is  due  to changes  in  the 
structure of the cell membrane or in its ability to repair  complement induced 
damage at certain intervals during the cell cycle. Therefore, this cell line  con- 
stitutes a useful model to investigate the final steps of the cytolytic reaction. 
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